References

References
1. Ablynx [Internet]. [2009]. Ghent, Belgium. [cited 2010 Mar 26]. Available from: http://www.ablynx.com

2. Carter P, Merchant AM. 1997. Engineering antibodies for imaging and therapy. Current Opinion in Biotechnology. 8:449-454.

3. Coppieters K, Dreier T, Silence K, de Haard H, Lauwereys M, Casteels P, Beirnaert E, Jonckheere H, Van de Wiele C, Staelens L, et al. 2006. Formatted anti-tumor necrosis factor VHH proteins derived from camelids show superior potency and targeting to inflamed joint sin a murine model of collagen-induced arthritis. Arthritis and Rheumatism. 54(6): 1856-1866

4. Cruz MA, Diacovo TG, Emsley J, Liddington R, Handin RI. 2000. Mapping the glycoprotein Ib-binding site in the von Willebrand Factor A1 domain. The Journal of Biological Chemistry. 275(25):19098-19105.

5. De Genst E, Silence K, Decanniere K, Conrath K, Loris R, Kinne J, Muyldermanns S, Wyns L. 2006. Molecular basis for the preferential cleft recognition by dromedary heavy chain antibodies. PNAS. 103(12):4586-4591.

6. De Meyre SF, De Maeyer B, Deckmyn H, Vanhoorelbeke K. 2009. Von Willebrand factor: drug and drug target. Cardiovascular & Haematological Disorders-Drug Targets. 9:9-20.

7. Elgert KD. 2009. Immunology: Understanding the Immune System. 2nd Edition. Hoboken, New Jersey: Wiley-Blackwell.

8. Deffar K, Shi H, Li L, Wang X, Zhu X. 2009. Nanobodies - the new concept in antibody engineering. African Journal of Biotechnology. 8(12):2645-2652.

9. Harmsen MM, De Haard HJ. 2007. Properties, production and applications of camelid single-domain antibody fragments. Applied Microbiology Biotechnology. 77:13-22.

10. Huizinga EG, Tsuji S, Romijn RAP, Schiphost ME, de Groot PG, Sixma JJ, Gros P. 2002. Structures of GPIb and its complex with vWF A1 domain. Science. 297:1176-1179.

 12. Journal of Thrombosis an dHaemostasis; Volume 5, Supplement 2: PP-WE-416

13. Majidi J, Barar J, Baradaran B, Abdolalizadeh J, Omidi Y. 2009. Target therapy of cancer: Implmenetation of monoclonal antibodies and nanobodies. Human Antibodies. 18:81-1

14. Muyldermans S. 2001. Single domain camel antibodies: current status. Molecular Biotechnology. 74:277-302.

15. Nested Primers for PCR [Internet]. [2002]. Department of Biology, Davidson College, Davidson, North Carolina, USA. [cited 2010 Apr 06]. Available from: http://www.bio.davidson.edu/courses/genomics/method/NestedPCR.html

16. Revets H, De Baetselier P, Muyldermans S. 2005. Nanobodies as novel agents for cancer therapy. Expert Opinion on Biological Therapy. 5(1):111-124.

17. Rabinowitz I, Tuley EA, Mancuso DJ, RANDI AM, Firkin BG, Howard MA, Sadler JE. 1992. von Willebrand disease type B: a missense mutation selectively abolishes ristocetin-induced von Willebrand factor binding to platelet glycoprotein Ib. Medical Sciences. 89:9846-9849.

18. Siller-Matula JM, Krumphuber J, Jilma B. 2010. Pharmacokinetic, pharmacodynamic and clinical profile of novel antiplatelet drugs targeting vascular diseases. British Journal of Pharmacology. 159:502-517.

19. Van Bockstaele F, Holz J, Revets H. 2009. The development of nanobodies for therapeutic application. Current Opinion in Investigational Drugs. 10(11):1212-1224.

20. Weslolowski J, Alzogaray V, Reyelt J, Unger M, Juarez K, Urrutia M, Cauerhff A, Danquah W, Rissiek B, Schwartz N, et al. 2009. Single Domain Antibodies: promising experimental and therapeutic tools in infection and immunity. Medical Microbiology and Immunology. 198:157-174.